APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Hepatic Encephalopathy Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Hepatic Encephalopathy Drug Industry Growth and Trends Forecast to 2032

Report ID 173997820119 December 202596 pages

Choose your research edition.

Industry ResearchHepatic Encephalopathy Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatic Encephalopathy Drug Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Hepatic Encephalopathy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatic Encephalopathy Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatic Encephalopathy Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Hepatic Encephalopathy Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Hepatic Encephalopathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Hepatic Encephalopathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hepatic Encephalopathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hepatic Encephalopathy Drug include Umecrine Cognition AB, Spherium Biomed S.L., Rebiotix Inc., Ocera Therapeutics, Inc., KannaLife Sciences, Inc., Horizon Pharma Plc, Cosmo Pharmaceuticals S.p.A and Alfa Wassermann S.p.A, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Hepatic Encephalopathy Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Hepatic Encephalopathy Drug market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Hepatic Encephalopathy Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Hepatic Encephalopathy Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Hepatic Encephalopathy Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Hepatic Encephalopathy Drug Market by Company

Umecrine Cognition AB

Spherium Biomed S.L.

Rebiotix Inc.

Ocera Therapeutics, Inc.

KannaLife Sciences, Inc.

Horizon Pharma Plc

Cosmo Pharmaceuticals S.p.A

Alfa Wassermann S.p.A

Hepatic Encephalopathy Drug Segment by Type

GR-3027

KLS-13019

RBX-2660

SYNB-1020

Others

Hepatic Encephalopathy Drug Segment by Application

Clinic

Hospital

Others

Hepatic Encephalopathy Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatic Encephalopathy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatic Encephalopathy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatic Encephalopathy Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hepatic Encephalopathy Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Hepatic Encephalopathy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of GR-3027 Table 2. Major Company of KLS-13019 Table 3. Major Company of RBX-2660 Table 4. Major Company of SYNB-1020 Table 5. Major Company of Others Table 6. Global Hepatic Encephalopathy Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (W Units) Table 8. Global Hepatic Encephalopathy Drug Sales Market Share in Volume by Type (2021-2026) Table 9. Global Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (US$ Million) Table 10. Global Hepatic Encephalopathy Drug Sales Market Share in Value by Type (2021-2026) Table 11. Global Hepatic Encephalopathy Drug Price by Type (2021-2026) & (US$/Unit) Table 12. Global Hepatic Encephalopathy Drug Sales by Type (2027-2032) & (W Units) Table 13. Global Hepatic Encephalopathy Drug Sales Market Share in Volume by Type (2027-2032) Table 14. Global Hepatic Encephalopathy Drug Sales by Type (2027-2032) & (US$ Million) Table 15. Global Hepatic Encephalopathy Drug Sales Market Share in Value by Type (2027-2032) Table 16. Global Hepatic Encephalopathy Drug Price by Type (2027-2032) & (US$/Unit) Table 17. North America Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (W Units) Table 18. North America Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (W Units) Table 20. Europe Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (W Units) Table 22. Asia-Pacific Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (W Units) Table 24. Latin America Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (W Units) Table 26. Middle East and Africa Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (US$ Million) Table 27. Hepatic Encephalopathy Drug Industry Trends Table 28. Hepatic Encephalopathy Drug Industry Drivers Table 29. Hepatic Encephalopathy Drug Industry Opportunities and Challenges Table 30. Hepatic Encephalopathy Drug Industry Restraints Table 31. Global Hepatic Encephalopathy Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Hepatic Encephalopathy Drug Revenue Market Share by Company (2021-2026) Table 33. Global Hepatic Encephalopathy Drug Sales by Company (2021-2026) & (W Units) Table 34. Global Hepatic Encephalopathy Drug Sales Share by Company (2021-2026) Table 35. Global Hepatic Encephalopathy Drug Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Hepatic Encephalopathy Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Hepatic Encephalopathy Drug Major Company Production Sites and Headquarters Table 38. Global Hepatic Encephalopathy Drug Company, Product Type & Application Table 39. Global Hepatic Encephalopathy Drug Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Hepatic Encephalopathy Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Hepatic Encephalopathy Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Hepatic Encephalopathy Drug Sales by Region (2021-2026) & (W Units) Table 44. Global Hepatic Encephalopathy Drug Sales Market Share in Volume by Region (2021-2026) Table 45. Global Hepatic Encephalopathy Drug Sales by Region (2021-2026) & (US$ Million) Table 46. Global Hepatic Encephalopathy Drug Sales Market Share in Value by Region (2021-2026) Table 47. Global Hepatic Encephalopathy Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Hepatic Encephalopathy Drug Sales by Region (2027-2032) & (W Units) Table 49. Global Hepatic Encephalopathy Drug Sales Market Share in Volume by Region (2027-2032) Table 50. Global Hepatic Encephalopathy Drug Sales by Region (2027-2032) & (US$ Million) Table 51. Global Hepatic Encephalopathy Drug Sales Market Share in Value by Region (2027-2032) Table 52. Global Hepatic Encephalopathy Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Hepatic Encephalopathy Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (W Units) Table 55. Global Hepatic Encephalopathy Drug Sales Market Share in Volume by Application (2021-2026) Table 56. Global Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (US$ Million) Table 57. Global Hepatic Encephalopathy Drug Sales Market Share in Value by Application (2021-2026) Table 58. Global Hepatic Encephalopathy Drug Price by Application (2021-2026) & (US$/Unit) Table 59. Global Hepatic Encephalopathy Drug Sales by Application (2027-2032) & (W Units) Table 60. Global Hepatic Encephalopathy Drug Sales Market Share in Volume by Application (2027-2032) Table 61. Global Hepatic Encephalopathy Drug Sales by Application (2027-2032) & (US$ Million) Table 62. Global Hepatic Encephalopathy Drug Sales Market Share in Value by Application (2027-2032) Table 63. Global Hepatic Encephalopathy Drug Price by Application (2027-2032) & (US$/Unit) Table 64. North America Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (W Units) Table 65. North America Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (W Units) Table 67. Europe Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (W Units) Table 69. Asia-Pacific Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (W Units) Table 71. Latin America Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (W Units) Table 73. Middle East and Africa Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (US$ Million) Table 74. Umecrine Cognition AB Company Information Table 75. Umecrine Cognition AB Business Overview Table 76. Umecrine Cognition AB Hepatic Encephalopathy Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Umecrine Cognition AB Hepatic Encephalopathy Drug Product Portfolio Table 78. Umecrine Cognition AB Recent Development Table 79. Spherium Biomed S.L. Company Information Table 80. Spherium Biomed S.L. Business Overview Table 81. Spherium Biomed S.L. Hepatic Encephalopathy Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Spherium Biomed S.L. Hepatic Encephalopathy Drug Product Portfolio Table 83. Spherium Biomed S.L. Recent Development Table 84. Rebiotix Inc. Company Information Table 85. Rebiotix Inc. Business Overview Table 86. Rebiotix Inc. Hepatic Encephalopathy Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Rebiotix Inc. Hepatic Encephalopathy Drug Product Portfolio Table 88. Rebiotix Inc. Recent Development Table 89. Ocera Therapeutics, Inc. Company Information Table 90. Ocera Therapeutics, Inc. Business Overview Table 91. Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Product Portfolio Table 93. Ocera Therapeutics, Inc. Recent Development Table 94. KannaLife Sciences, Inc. Company Information Table 95. KannaLife Sciences, Inc. Business Overview Table 96. KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Product Portfolio Table 98. KannaLife Sciences, Inc. Recent Development Table 99. Horizon Pharma Plc Company Information Table 100. Horizon Pharma Plc Business Overview Table 101. Horizon Pharma Plc Hepatic Encephalopathy Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Horizon Pharma Plc Hepatic Encephalopathy Drug Product Portfolio Table 103. Horizon Pharma Plc Recent Development Table 104. Cosmo Pharmaceuticals S.p.A Company Information Table 105. Cosmo Pharmaceuticals S.p.A Business Overview Table 106. Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Product Portfolio Table 108. Cosmo Pharmaceuticals S.p.A Recent Development Table 109. Alfa Wassermann S.p.A Company Information Table 110. Alfa Wassermann S.p.A Business Overview Table 111. Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Product Portfolio Table 113. Alfa Wassermann S.p.A Recent Development Table 114. North America Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 115. North America Hepatic Encephalopathy Drug Sales by Country (2021-2026) & (W Units) Table 116. North America Hepatic Encephalopathy Drug Sales Market Share by Country (2021-2026) Table 117. North America Hepatic Encephalopathy Drug Sales Forecast by Country (2027-2032) & (W Units) Table 118. North America Hepatic Encephalopathy Drug Sales Market Share Forecast by Country (2027-2032) Table 119. North America Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 120. North America Hepatic Encephalopathy Drug Market Size by Country (2021-2026) & (US$ Million) Table 121. North America Hepatic Encephalopathy Drug Market Share by Country (2021-2026) Table 122. North America Hepatic Encephalopathy Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 123. North America Hepatic Encephalopathy Drug Market Share Forecast by Country (2027-2032) Table 124. Europe Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 125. Europe Hepatic Encephalopathy Drug Sales by Country (2021-2026) & (W Units) Table 126. Europe Hepatic Encephalopathy Drug Sales Market Share by Country (2021-2026) Table 127. Europe Hepatic Encephalopathy Drug Sales Forecast by Country (2027-2032) & (W Units) Table 128. Europe Hepatic Encephalopathy Drug Sales Market Share Forecast by Country (2027-2032) Table 129. Europe Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 130. Europe Hepatic Encephalopathy Drug Market Size by Country (2021-2026) & (US$ Million) Table 131. Europe Hepatic Encephalopathy Drug Market Share by Country (2021-2026) Table 132. Europe Hepatic Encephalopathy Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 133. Europe Hepatic Encephalopathy Drug Market Share Forecast by Country (2027-2032) Table 134. Asia-Pacific Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 135. Asia-Pacific Hepatic Encephalopathy Drug Sales by Country (2021-2026) & (W Units) Table 136. Asia-Pacific Hepatic Encephalopathy Drug Sales Market Share by Country (2021-2026) Table 137. Asia-Pacific Hepatic Encephalopathy Drug Sales Forecast by Country (2027-2032) & (W Units) Table 138. Asia-Pacific Hepatic Encephalopathy Drug Sales Market Share Forecast by Country (2027-2032) Table 139. Asia-Pacific Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 140. Asia-Pacific Hepatic Encephalopathy Drug Market Size by Country (2021-2026) & (US$ Million) Table 141. Asia-Pacific Hepatic Encephalopathy Drug Market Share by Country (2021-2026) Table 142. Asia-Pacific Hepatic Encephalopathy Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 143. Asia-Pacific Hepatic Encephalopathy Drug Market Share Forecast by Country (2027-2032) Table 144. Latin America Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 145. Latin America Hepatic Encephalopathy Drug Sales by Country (2021-2026) & (W Units) Table 146. Latin America Hepatic Encephalopathy Drug Sales Market Share by Country (2021-2026) Table 147. Latin America Hepatic Encephalopathy Drug Sales Forecast by Country (2027-2032) & (W Units) Table 148. Latin America Hepatic Encephalopathy Drug Sales Market Share Forecast by Country (2027-2032) Table 149. Latin America Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 150. Latin America Hepatic Encephalopathy Drug Market Size by Country (2021-2026) & (US$ Million) Table 151. Latin America Hepatic Encephalopathy Drug Market Share by Country (2021-2026) Table 152. Latin America Hepatic Encephalopathy Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 153. Latin America Hepatic Encephalopathy Drug Market Share Forecast by Country (2027-2032) Table 154. Middle East and Africa Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 155. Middle East and Africa Hepatic Encephalopathy Drug Sales by Country (2021-2026) & (W Units) Table 156. Middle East and Africa Hepatic Encephalopathy Drug Sales Market Share by Country (2021-2026) Table 157. Middle East and Africa Hepatic Encephalopathy Drug Sales Forecast by Country (2027-2032) & (W Units) Table 158. Middle East and Africa Hepatic Encephalopathy Drug Sales Market Share Forecast by Country (2027-2032) Table 159. Middle East and Africa Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 160. Middle East and Africa Hepatic Encephalopathy Drug Market Size by Country (2021-2026) & (US$ Million) Table 161. Middle East and Africa Hepatic Encephalopathy Drug Market Share by Country (2021-2026) Table 162. Middle East and Africa Hepatic Encephalopathy Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 163. Middle East and Africa Hepatic Encephalopathy Drug Market Share Forecast by Country (2027-2032) Table 164. Key Raw Materials Table 165. Raw Materials Key Suppliers Table 166. Hepatic Encephalopathy Drug Distributors List Table 167. Hepatic Encephalopathy Drug Customers List Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources Table 171. Primary Sources List of Figures Figure 1. Hepatic Encephalopathy Drug Image Figure 2. Global Hepatic Encephalopathy Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatic Encephalopathy Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Hepatic Encephalopathy Drug Sales (2021-2032) & (W Units) Figure 5. GR-3027 Image Figure 6. Global GR-3027 Sales YoY Growth (2021-2032) & (W Units) Figure 7. KLS-13019 Image Figure 8. Global KLS-13019 Sales YoY Growth (2021-2032) & (W Units) Figure 9. RBX-2660 Image Figure 10. Global RBX-2660 Sales YoY Growth (2021-2032) & (W Units) Figure 11. SYNB-1020 Image Figure 12. Global SYNB-1020 Sales YoY Growth (2021-2032) & (W Units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 15. Global Hepatic Encephalopathy Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Hepatic Encephalopathy Drug Market Share by Type 2025 VS 2032 Figure 17. North America Hepatic Encephalopathy Drug Sales Market Share in Volume by Type in 2025 Figure 18. North America Hepatic Encephalopathy Drug Sales Market Share in Value by Type in 2025 Figure 19. Europe Hepatic Encephalopathy Drug Sales Market Share in Volume by Type in 2025 Figure 20. Europe Hepatic Encephalopathy Drug Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Hepatic Encephalopathy Drug Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Hepatic Encephalopathy Drug Sales Market Share in Value by Type in 2025 Figure 23. Latin America Hepatic Encephalopathy Drug Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Hepatic Encephalopathy Drug Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Hepatic Encephalopathy Drug Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Hepatic Encephalopathy Drug Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Hepatic Encephalopathy Drug Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Clinic Image Figure 30. Global Clinic Sales YoY Growth (2021-2032) & (W Units) Figure 31. Hospital Image Figure 32. Global Hospital Sales YoY Growth (2021-2032) & (W Units) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 35. Global Hepatic Encephalopathy Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Hepatic Encephalopathy Drug Market Share by Application 2025 VS 2032 Figure 37. North America Hepatic Encephalopathy Drug Sales Market Share in Volume by Application in 2025 Figure 38. North America Hepatic Encephalopathy Drug Sales Market Share in Value by Application in 2025 Figure 39. Europe Hepatic Encephalopathy Drug Sales Market Share in Volume by Application in 2025 Figure 40. Europe Hepatic Encephalopathy Drug Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Hepatic Encephalopathy Drug Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Hepatic Encephalopathy Drug Sales Market Share in Value by Application in 2025 Figure 43. Latin America Hepatic Encephalopathy Drug Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Hepatic Encephalopathy Drug Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Hepatic Encephalopathy Drug Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Hepatic Encephalopathy Drug Sales Market Share in Value by Application in 2025 Figure 47. North America Hepatic Encephalopathy Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 48. North America Hepatic Encephalopathy Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Hepatic Encephalopathy Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Hepatic Encephalopathy Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Hepatic Encephalopathy Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 52. Europe Hepatic Encephalopathy Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Hepatic Encephalopathy Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Hepatic Encephalopathy Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Hepatic Encephalopathy Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 56. Asia-Pacific Hepatic Encephalopathy Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Hepatic Encephalopathy Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Hepatic Encephalopathy Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Hepatic Encephalopathy Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 60. Latin America Hepatic Encephalopathy Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Hepatic Encephalopathy Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Hepatic Encephalopathy Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Hepatic Encephalopathy Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 64. Middle East and Africa Hepatic Encephalopathy Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Hepatic Encephalopathy Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Hepatic Encephalopathy Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Hepatic Encephalopathy Drug Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Hepatic Encephalopathy Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • GR-3027
  • KLS-13019
  • RBX-2660
  • SYNB-1020
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Umecrine Cognition AB
  • Spherium Biomed S.L.
  • Rebiotix Inc.
  • Ocera Therapeutics, Inc.
  • KannaLife Sciences, Inc.
  • Horizon Pharma Plc
  • Cosmo Pharmaceuticals S.p.A
  • Alfa Wassermann S.p.A

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hepatic Encephalopathy Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Hepatic Encephalopathy Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Hepatic Encephalopathy Drug Market by Type
  6. 1.3.1 GR-3027
  7. 1.3.2 KLS-13019
  8. 1.3.3 RBX-2660
  9. 1.3.4 SYNB-1020
  10. 1.3.5 Others
  11. 1.4 Global Hepatic Encephalopathy Drug Market Size by Type
  12. 1.4.1 Global Hepatic Encephalopathy Drug Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Hepatic Encephalopathy Drug Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Hepatic Encephalopathy Drug Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Hepatic Encephalopathy Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Hepatic Encephalopathy Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Hepatic Encephalopathy Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Hepatic Encephalopathy Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Hepatic Encephalopathy Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Hepatic Encephalopathy Drug Industry Trends
  2. 2.2 Hepatic Encephalopathy Drug Industry Drivers
  3. 2.3 Hepatic Encephalopathy Drug Industry Opportunities and Challenges
  4. 2.4 Hepatic Encephalopathy Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Hepatic Encephalopathy Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Hepatic Encephalopathy Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Hepatic Encephalopathy Drug Price (2021-2026)
  4. 3.4 Global Hepatic Encephalopathy Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hepatic Encephalopathy Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Hepatic Encephalopathy Drug Company, Product Type & Application
  7. 3.7 Global Hepatic Encephalopathy Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hepatic Encephalopathy Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hepatic Encephalopathy Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hepatic Encephalopathy Drug Tier 1, Tier 2, and Tier 3
4 Hepatic Encephalopathy Drug Regional Status and Outlook
  1. 4.1 Global Hepatic Encephalopathy Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Hepatic Encephalopathy Drug Historic Market Size by Region
  3. 4.2.1 Global Hepatic Encephalopathy Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Hepatic Encephalopathy Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Hepatic Encephalopathy Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Hepatic Encephalopathy Drug Forecasted Market Size by Region
  7. 4.3.1 Global Hepatic Encephalopathy Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Hepatic Encephalopathy Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Hepatic Encephalopathy Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Hepatic Encephalopathy Drug by Application
  1. 5.1 Hepatic Encephalopathy Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Hepatic Encephalopathy Drug Market Size by Application
  6. 5.2.1 Global Hepatic Encephalopathy Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Hepatic Encephalopathy Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Hepatic Encephalopathy Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Hepatic Encephalopathy Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Hepatic Encephalopathy Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Hepatic Encephalopathy Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Hepatic Encephalopathy Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Hepatic Encephalopathy Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Umecrine Cognition AB
  2. 6.1.1 Umecrine Cognition AB Company Information
  3. 6.1.2 Umecrine Cognition AB Business Overview
  4. 6.1.3 Umecrine Cognition AB Hepatic Encephalopathy Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Umecrine Cognition AB Hepatic Encephalopathy Drug Product Portfolio
  6. 6.1.5 Umecrine Cognition AB Recent Developments
  7. 6.2 Spherium Biomed S.L.
  8. 6.2.1 Spherium Biomed S.L. Company Information
  9. 6.2.2 Spherium Biomed S.L. Business Overview
  10. 6.2.3 Spherium Biomed S.L. Hepatic Encephalopathy Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Spherium Biomed S.L. Hepatic Encephalopathy Drug Product Portfolio
  12. 6.2.5 Spherium Biomed S.L. Recent Developments
  13. 6.3 Rebiotix Inc.
  14. 6.3.1 Rebiotix Inc. Company Information
  15. 6.3.2 Rebiotix Inc. Business Overview
  16. 6.3.3 Rebiotix Inc. Hepatic Encephalopathy Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Rebiotix Inc. Hepatic Encephalopathy Drug Product Portfolio
  18. 6.3.5 Rebiotix Inc. Recent Developments
  19. 6.4 Ocera Therapeutics, Inc.
  20. 6.4.1 Ocera Therapeutics, Inc. Company Information
  21. 6.4.2 Ocera Therapeutics, Inc. Business Overview
  22. 6.4.3 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Product Portfolio
  24. 6.4.5 Ocera Therapeutics, Inc. Recent Developments
  25. 6.5 KannaLife Sciences, Inc.
  26. 6.5.1 KannaLife Sciences, Inc. Company Information
  27. 6.5.2 KannaLife Sciences, Inc. Business Overview
  28. 6.5.3 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Product Portfolio
  30. 6.5.5 KannaLife Sciences, Inc. Recent Developments
  31. 6.6 Horizon Pharma Plc
  32. 6.6.1 Horizon Pharma Plc Company Information
  33. 6.6.2 Horizon Pharma Plc Business Overview
  34. 6.6.3 Horizon Pharma Plc Hepatic Encephalopathy Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Horizon Pharma Plc Hepatic Encephalopathy Drug Product Portfolio
  36. 6.6.5 Horizon Pharma Plc Recent Developments
  37. 6.7 Cosmo Pharmaceuticals S.p.A
  38. 6.7.1 Cosmo Pharmaceuticals S.p.A Company Information
  39. 6.7.2 Cosmo Pharmaceuticals S.p.A Business Overview
  40. 6.7.3 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Product Portfolio
  42. 6.7.5 Cosmo Pharmaceuticals S.p.A Recent Developments
  43. 6.8 Alfa Wassermann S.p.A
  44. 6.8.1 Alfa Wassermann S.p.A Company Information
  45. 6.8.2 Alfa Wassermann S.p.A Business Overview
  46. 6.8.3 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Product Portfolio
  48. 6.8.5 Alfa Wassermann S.p.A Recent Developments
7 North America by Country
  1. 7.1 North America Hepatic Encephalopathy Drug Sales by Country
  2. 7.1.1 North America Hepatic Encephalopathy Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Hepatic Encephalopathy Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Hepatic Encephalopathy Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Hepatic Encephalopathy Drug Market Size by Country
  6. 7.2.1 North America Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Hepatic Encephalopathy Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Hepatic Encephalopathy Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Hepatic Encephalopathy Drug Sales by Country
  2. 8.1.1 Europe Hepatic Encephalopathy Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Hepatic Encephalopathy Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Hepatic Encephalopathy Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Hepatic Encephalopathy Drug Market Size by Country
  6. 8.2.1 Europe Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Hepatic Encephalopathy Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Hepatic Encephalopathy Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Hepatic Encephalopathy Drug Sales by Country
  2. 9.1.1 Asia-Pacific Hepatic Encephalopathy Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Hepatic Encephalopathy Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Hepatic Encephalopathy Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Hepatic Encephalopathy Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Hepatic Encephalopathy Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Hepatic Encephalopathy Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Hepatic Encephalopathy Drug Sales by Country
  2. 10.1.1 South America Hepatic Encephalopathy Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Hepatic Encephalopathy Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Hepatic Encephalopathy Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Hepatic Encephalopathy Drug Market Size by Country
  6. 10.2.1 South America Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Hepatic Encephalopathy Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Hepatic Encephalopathy Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Hepatic Encephalopathy Drug Sales by Country
  2. 11.1.1 Middle East and Africa Hepatic Encephalopathy Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Hepatic Encephalopathy Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Hepatic Encephalopathy Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Hepatic Encephalopathy Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Hepatic Encephalopathy Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Hepatic Encephalopathy Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Hepatic Encephalopathy Drug Value Chain Analysis
  2. 12.1.1 Hepatic Encephalopathy Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Hepatic Encephalopathy Drug Production Mode & Process
  7. 12.2 Hepatic Encephalopathy Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Hepatic Encephalopathy Drug Distributors
  10. 12.2.3 Hepatic Encephalopathy Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst